U.S. Consumer Durables Stock News

Black Diamond Therapeutics (BDTX) just released topline Phase 2 data for its EGFR inhibitor silevertinib in frontline non small cell lung cancer, while also laying out plans for a randomized Phase 2 trial in newly diagnosed glioblastoma. See our latest analysis for Black Diamond Therapeutics. The latest silevertinib update landed against a choppy backdrop for Black Diamond Therapeutics, with a sharp 1 day share price return of negative 22.03 percent and a 7 day share price return of negative...

Wondering if Kellanova is still fairly priced after its long run, or if there is more upside left in the tank? This breakdown will help you decide whether the current share price actually makes sense. The stock has been mostly treading water in the short term, down 0.6% over the last week and roughly flat over the past month at 0.1%. However, that hides a steadier climb of 2.6% year to date and 6.2% over the last year, compounding into 32.5% and 69.5% gains over the past 3 and 5...

TJX Companies (TJX) just posted another solid quarter, with Q3 2026 revenue of about $15.1 billion, Basic EPS of $1.28, and net income of $1.4 billion setting the tone for its latest update. The company has seen revenue move from roughly $14.1 billion and EPS of $1.15 in Q3 2025 to $15.1 billion and $1.28 this quarter, while trailing twelve month revenue has climbed to about $59.0 billion alongside EPS of $4.58 and net income of $5.1 billion, giving investors a clear view of steady top and...

Oppenheimer recently initiated coverage on Theravance Biopharma with an Outperform rating, emphasizing the importance of the Phase 3 ampreloxetine readout expected in the first quarter of 2026 and the company’s virtual key opinion leader event on this program. The focus on ampreloxetine as a potential billion-dollar therapy in a rare neurogenic condition highlights how pivotal this single late-stage asset has become for Theravance’s future prospects and risk profile. We’ll now explore how...

Blue Hat Interactive Entertainment Technology (NasdaqCM:BHAT) has just posted its H1 2025 scorecard, with trailing twelve month revenue sitting at about $19.0 million and net income of roughly -$9.1 million, keeping EPS around $0 over that span. The company has seen revenue move from $27.4 million in H2 2023 to $18.7 million in H2 2024, while net income excluding extraordinary items shifted from -$22.3 million to -$8.2 million. The latest numbers still leave investors focused squarely on...

On November 25, 2025, Evertec, Inc. and its subsidiary Evertec Group, LLC entered into a fifth amendment to their Credit Agreement, adding a US$150,000,000 Term Loan B facility to repay borrowings under the existing revolving credit line at unchanged interest margins. This refinancing shifts short-term revolver usage into longer-term term debt, potentially giving EVERTEC clearer liquidity visibility and more stable funding for its operations and growth initiatives. We’ll now examine how...

Waterdrop (NYSE:WDH) has followed up its latest quarter with solid headline numbers, as Q2 2025 revenue came in at about CNY 838 million and basic EPS landed at roughly CNY 0.39, which sets the stage for another year of profitability momentum. The company has seen revenue move from roughly CNY 676 million in Q2 2024 to about CNY 838 million in Q2 2025, while basic EPS has climbed from around CNY 0.24 to CNY 0.39 over the same period. This gives investors a cleaner, more scalable earnings...

Okta (OKTA) has just posted Q3 2026 numbers with revenue of $742 million and basic EPS of $0.24, while on a trailing twelve month basis revenue sits at about $2.8 billion with EPS of $1.12 as the business continues to consolidate its move into sustained profitability. Looking back over recent quarters, revenue has stepped up from $682 million in Q4 2025 and $665 million in Q3 2025, alongside basic EPS rising from $0.13 and $0.09 in those periods. This sets the stage for investors to focus on...

CrowdStrike Holdings (CRWD) just posted Q3 2026 results with revenue of about $1.2 billion and a basic EPS loss of $0.14, keeping the focus firmly on scaling the top line while chipping away at losses. The company has seen quarterly revenue move from roughly $964 million in Q2 2025 to $1.23 billion in Q3 2026. Basic EPS has shifted from a $0.19 profit in Q2 2025 to a $0.44 loss in Q1 2026 and then narrowed to a $0.14 loss this quarter. This progression positions investors to pay close...

Marvell Technology (MRVL) has turned in a punchy Q3 2026 print, with revenue of about $2.1 billion and basic EPS of $2.22, while net income (excluding extra items) came in at $1.9 billion as the latest marker of its profitability turnaround. The company has seen revenue move from $1.52 billion in Q3 2025 to $2.07 billion in Q3 2026 alongside a swing in net income from a loss of $676.3 million to a $1.9 billion profit, setting up a quarter where margins look materially healthier and far more...

Janux Therapeutics recently reported positive updated interim Phase 1 data for its PSMA-directed TRACTr candidate JANX007 in metastatic castration-resistant prostate cancer, based on 109 treated patients as of the October 15, 2025 cutoff, and held a virtual event on December 1 to discuss the results. The update highlights not only progress for JANX007 but also reinforces Janux’s broader TRACTr and ARM platforms, which span multiple solid tumors and an emerging CD19 program in autoimmune...

Asana (ASAN) just posted its Q3 2026 numbers, with revenue at about $201 million and basic EPS at roughly -$0.29. This keeps the focus firmly on how quickly the business can convert top line scale into a path toward profitability. The company has seen revenue move from around $179 million in Q2 2025 to roughly $201 million in Q3 2026, while basic EPS over that span has hovered between about -$0.31 and -$0.17. That sets up this quarter as another check in on whether margins are starting to...

The board of NetApp, Inc. ( NASDAQ:NTAP ) has announced that it will pay a dividend of $0.52 per share on the 21st of...

Signet Jewelers (SIG) has just posted Q3 2026 results with revenue of $1.4 billion and basic EPS of $0.49, setting the stage for investors to reassess the trajectory after a choppy first half. The company has seen quarterly revenue move from $1.49 billion in Q2 2025 to $1.35 billion in Q3 2025 and then to $1.39 billion in Q3 2026, while basic EPS has swung from a loss of $2.28 in Q2 2025 to $0.12 in Q3 2025 and $0.49 in the latest quarter. This puts the focus firmly on how sustainable the...

Recent data showing a sharp drop in trading volume but steady growth in verified accounts at Coincheck Group (CNCK) has investors rethinking how this crypto exchange makes money and where future growth might come from. See our latest analysis for Coincheck Group. Despite the weak year to date share price return and a 1 year total shareholder return of around minus 49 percent, the recent 7 day share price return of roughly 103 percent and 30 day gain near 78 percent suggest momentum is...

Investors were underwhelmed by the solid earnings posted by Veeva Systems Inc. ( NYSE:VEEV ) recently. We have done...

In recent sessions, major U.S. stock indexes have shown resilience, rising despite initial declines due to disappointing private payroll data and adjustments in tech sector sales strategies. As investors navigate these fluctuating conditions, identifying stocks trading below their intrinsic value can offer potential opportunities for those looking to capitalize on market inefficiencies.

As the U.S. stock market continues to show resilience, with major indexes like the Dow Jones and S&P 500 experiencing gains despite mixed economic signals such as a decline in private payrolls, investors are increasingly looking towards companies with solid growth potential and strong insider ownership. In this environment, stocks where insiders hold significant stakes can be particularly appealing, as they often indicate confidence in the company's future prospects and alignment of interests...

As the U.S. markets show resilience with major indexes rising despite mixed economic signals, investors are increasingly looking beyond traditional stocks to explore other opportunities. Penny stocks, often associated with smaller or newer companies, remain an intriguing area for those seeking potential value in less conventional investments. While the term may seem outdated, these stocks can still offer significant opportunities when backed by robust financials and a clear growth path.

If you are wondering whether Stewart Information Services is still good value after its run up, or if most of the upside is already priced in, you are not alone. The stock has climbed 11.4% over the last month and is up 16.2% year to date, adding to gains of 96.9% over three years. Recently, investors have been watching sector wide shifts in real estate activity and transaction volumes, which directly influence demand for Stewart's title and closing services. Broader optimism around property...

Jiayin Group (JFIN) just posted third quarter 2025 results that caught investors attention, with net income jumping sharply and sales ticking higher compared to last year, underscoring how its lending platform is scaling profitably. See our latest analysis for Jiayin Group. The market has not fully rewarded that progress yet. The share price is $6.76, and a steep 3 month share price return of minus 44.73 percent contrasts with a powerful 3 year total shareholder return of 309.48 percent. This...

If you are wondering whether Belite Bio's rapid rise is backed by real value or driven by hype, this article will walk you through what the numbers are really saying about the stock. After a sharp move higher, with the share price up 16.4% over the last week, 34.2% over the last month, and an eye catching 132.9% year to date, the market is clearly re rating the story and its risk profile. Much of the excitement has centered around Belite Bio's late stage ophthalmology pipeline, particularly...

Over the past year, many SPX Technologies, Inc. ( NYSE:SPXC ) insiders sold a significant stake in the company which...

If you have been wondering whether Central Garden & Pet at around $33.63 is quietly turning into a value opportunity or just a value trap, you are not alone. The stock is down about 11.8% year to date and 17.6% over the last year, even though it has managed positive annualized returns of roughly 10.5% over 3 years and 13.1% over 5 years, a mix that hints at both recovery potential and shifting risk sentiment. Recent headlines have focused on Central Garden & Pet sharpening its portfolio...